Key Investor Signals
1,500 patients prescribed Noxxea; nearly 260 physicians registered
Di & Care reports that Noxxea has passed 1,500 prescribed patients, with nearly 260 physicians registered on its prescribing platform. Each prescription opens a four-week treatment course.
Insomnia severity fell 9.4 points at 3-month follow-up
In the multicenter REST-NOXXEA study, insomnia severity fell by an average of 7.32 points after four weeks of treatment. At the three-month follow-up, scores were down 9.4 points from baseline, with 87% of 61 patients no longer reporting moderate or severe insomnia.
CE-marked prescription treatment, live with doctors
Noxxea is CE marked as a medical device under MDR 2017/745 and available by physician prescription through Di & Care's own prescribing and follow-up platform.
Other Positive Signals
- Selected for Challenges' 100 Startups to Invest in 2026 ranking.
- Published the Noxxea treatment framework in peer-reviewed JMIR Human Factors.
- Won three external awards in psychiatry, business, and startup competitions since 2024.
- Received the French Tech Seed label in March 2026.
Team
Anthony Dubroc
Chief Executive Officer
- Managing Director for Servier in Finland and Estonia from 2009 to 2011. Held market access responsibility for both countries.
- Ran Servier's operations for Romania and Ukraine from 2007 to 2009, opening the Moldovan market.
- Marketing Director for Sanofi's thrombosis range, where he led the launch of the anticoagulant Arixtra.
- Founded MySommeil in 2012 and has operated the sleep and shift-work consultancy for employers ever since.
Charles de la Personne
Chief Scientific Officer and Co-founder
- Doctor of pharmacy from Université de Lorraine. Holds an inter-university diploma in sleep and its pathology.
- Spent six years at Sobi across specialty care, rare disease and hospital products. Left as Marketing and Sales Effectiveness Manager for France.
- Partner and director at MySommeil since 2017, training employers on shift work and vigilance.
- Ran his own health consultancy, dlP Conseil&Santé, from 2017 to 2019.
Product
Di & Care builds prescription treatment apps for sleep and mental health. Noxxea, its first product, treats chronic insomnia in adults. It targets the gap between the therapy guidance recommends and what a family doctor can deliver.
Noxxea has been available on prescription since November 2025. The company reports more than 1,500 prescribed patients and nearly 260 physicians registered on its prescribing platform by September 2026, alongside first study results.
Chronic insomnia treated by a family doctor
Most chronic insomnia is handled by a family doctor rather than in a sleep center. Those doctors can write a prescription for a sleeping pill or refer to a specialist. Noxxea gives them a third option they can issue in the same visit.
A four-week program that needs no therapist appointment
Noxxea delivers the same protocol a specialist would use, without needing the specialist's time. Four guided sessions and short videos take the patient through it. Di & Care states that eight algorithms adapt the content to what each patient records about their own sleep.
Its own prescribing platform for doctors
Every course starts with a doctor, on a platform Di & Care built and runs. That gives the company direct access to prescribers and a record of every course delivered.
Market Overview
Behavioral therapy is the recommended first treatment for chronic insomnia in France, but access to trained specialists remains limited. Many patients instead receive sleeping medication, even though benzodiazepine use is intended to remain short term.
Prescription digital treatments can expand access by delivering behavioral therapy without requiring repeated specialist appointments. France has also created a reimbursement pathway for digital medical devices, providing a potential route for prescription insomnia programs to be funded through the healthcare system.
Share of adults aged 18 to 79 reporting difficulty falling asleep or night waking at least three nights a week.
Patients in France using benzodiazepines beyond the recommended treatment duration.
Maximum annual reimbursement available under France’s PECAN pathway for eligible prescription digital medical devices.
Projected market growth from 2024 to 2030.
Comparable Outcomes
Mementor
Mementor developed Somnio, a prescription app delivering behavioral treatment for chronic insomnia. German insurers approved it for permanent reimbursement, allowing doctors to prescribe it directly. ResMed acquired Mementor in 2022 for an undisclosed amount. German statutory insurers had recorded 67,400 activated prescriptions and €16.4 million in reimbursements since 2020 for a treatment course priced at €224.99.
Itamar Medical
Itamar Medical developed WatchPAT, a device for diagnosing sleep apnea at home. It moved sleep testing outside specialist laboratories and made it easier to access. The company provides a precedent for building strategic value in accessible sleep medicine. ZOLL Medical acquired Itamar Medical in 2021 in a transaction valued at approximately $538 million.
Idorsia
Idorsia developed daridorexant, an oral insomnia treatment sold as Quviviq in the United States and Europe. The drug also produced positive results in a Japanese Phase 3 trial. Idorsia sold its Asia-Pacific operations outside China to Sosei Heptares in 2023 for CHF 400 million. The transaction included its Japanese and Korean affiliates, Pivlaz rights and regional daridorexant rights.
Interested in More Startups Like Di & Care?
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.